Efficacy and Safety of Apixaban in Reducing Restenosis and Limb Loss in PAD Patients. (AGRIPPA)

Science Valley Research Institute

Status and phase: Unknown; Phase 3

Conditions: Critical Limb Ischemia

Treatments: Drug: Clopidogrel 75mg; Drug: ASA; Drug: Apixaban

Study type: Interventional

Funder types: Other; Industry

Identifiers

NCT04229264

AGRIPPA/EMRISTA 2018

Details and patient eligibility

About

This study will evaluate the efficacy and safety of apixaban 2.5 mg twice daily plus aspirin compared to the standard treatment (clopidogrel plus aspirin) in patients with critical limb ischemia undergoing infrapopliteal arterial endovascular intervention.

Full description

This study is a multicentre, parallel-group, prospective, randomized open-label, blinded-endpoint adjudication, proof-of-concept, and exploratory trial. Two hundred patients will be randomized in a 1:1 ratio, 72 hours after successful infrapopliteal angioplasty for critical limb ischemia. In the study group, patients will receive oral apixaban 2.5mg twice daily plus aspirin 100 mg once-daily for 12 months. In the control group, aspirin 100 mg once-daily will be taken for 1 year on a background of clopidogrel (75mg daily) for the first three months. The primary endpoint is the composite of target lesion revascularization (TLR), major amputation or restenosis/occlusion (RAS) plus MACE (myocardial infarction, stroke, and cardiovascular death) at 12 months. The primary safety endpoint is the composite of major bleeding and clinically relevant non-major bleeding at 12 months.

Enrollment: 200 estimated patients

Sex: All

Ages: 18+ years old

Volunteers: No Healthy Volunteers

Inclusion criteria

• Written informed consent.
• Age>18 years old.
• Negative serum pregnancy test (in women of childbearing only).
• Patients submitted to endovascular procedures below-the-knee by not exclusively.
• Patient understands and is willing and able to comply with the study instructions and follow-up visit.
• More than 70% stenosis or occlusion of the three distal arteries including or not the tibiofibular trunk (TFT).
• Tissue loss (Rutherford 5).
• One or more patent vessel of pedal arch.

Exclusion criteria

• TASC II D femoral and/or popliteal occlusion.
• Life expectancy less than 1 year.
• Allergy or contraindication to apixaban treatment.
• Allergy or contraindication to dual antiplatelet treatment.
• Creatinine clearance less than 30mL/min.
• Planned major amputation before procedure.
• Hybrid procedure (open and endovascular).
• Use of fibrinolytic in the past 10 days.
• Known HIV infection.
• Liver disease (acute or chronic hepatitis and cirrhosis).
• Drug addiction or alcohol abuse 12 months before the randomization.
• Concomitant medications thatinhibit the CYP 3A4 cytochrome and P glycoprotein (ketoconazole, Iitraconazole, ritonavir).
• Platelets count inferior to 100x109/L.
• INR more than 1.5.
• History or condition with high risk of bleeding: Eg. Trauma within 30 days before randomization, gastrointestinal bleeding 6 month before the randomization, intra-ocular, spinal, intra-articular bleeding (any time before), AV malformation, cerebral aneurysm and hypertension without control.

Trial design

Primary purpose: Treatment

Allocation: Randomized

Interventional model: Parallel Assignment

Masking: None (Open label)

---

200 participants in 2 patient groups

Control group

Active Comparator group

Description:

Aspirin 100 mg (oral, once-daily) for 1 year plus Clopidogrel 75 mg (oral, once-daily) for 3 months.

Treatment:

Drug: ASA

Drug: Clopidogrel 75mg

Apixaban group

Experimental group

Description:

Apixaban 2.5 mg (oral, twice daily) for 1 year plus Aspirin 100 mg (oral, once-daily) for 1 year.

Treatment:

Drug: ASA

Drug: Apixaban